Lophar SRL
1.5 FTEThe score of Lophar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets -3 % Headcount (avg FTE) +88 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Lophar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 147,094 € | ||||
| Equity | 827,386 € | ||||
| Cash | 172,558 € | ||||
| EBITDA | 181,586 € | ||||
| Total assets | €1.33m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 11 Aug 2026
- Year ended 31 Dec 2024filed on 23 Jul 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Lophar's financial analysis
- Solvency62.4%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Lophar
Lophar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0876.287.310
- VAT number
- BE0876287310
- Peppol
- Registered · 0208:0876287310 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Sep 2005
- Registered office
- 9880 Aalter
- Size
- Micro · 1.5 FTE
- Latest accounts
- 2025 · filed on 11 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Lophar (SRL) has been based in Aalter since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 147,094 € and equity of 827,386 €; its revenue is not published. With 1.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 62.4%, above the median of its sector (44.2%).
Companies similar to Lophar
Companies in the same business, of comparable size and area, outside its group.
- Fortilab Manufacture of pharmaceutical preparations Etterbeek · balance sheet €1.39m
- Pharmacie de Vesnau Manufacture of pharmaceutical preparations Ittre · balance sheet €1.25m
- HEW Pharma Manufacture of pharmaceutical preparations Kalmthout · balance sheet €1.01m
- Pannoc Chemie Manufacture of pharmaceutical preparations Olen · balance sheet €2.32m
- Clarethis Manufacture of basic pharmaceutical products Soignies · balance sheet 172,781 €
- Vesale Pharma Woman Health Wholesale of pharmaceutical and medical goods Éghezée · balance sheet 62,158 €
- Apotheke Reul Retail sale of pharmaceutical products Eupen · balance sheet €1.44m
- Diepenbeek Markt Farma Retail sale of pharmaceutical products Diepenbeek · balance sheet 505,908 €
Frequently asked questions about Lophar
What is the revenue of Lophar?
Lophar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Lophar?
In Belgium, the VAT number is the company number prefixed with BE: BE0876287310 for Lophar, if the company is VAT-registered. Its company number (CBE) is 0876.287.310.
Where is the registered office of Lophar?
According to the CBE register, the registered office of Lophar is in 9880 Aalter.
What is the equity of Lophar?
At the close of the 2025 financial year, the equity of Lophar amounts to 827,386 €, a solvency of 62.4% of total assets.
How many people work at Lophar?
1.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Lophar?
The register lists 2 active mandates at Lophar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Lophar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →